Updates on CCP Virus: FDA Authorizes Johnson & Johnson Single Dose Vaccine
The Food and Drug Administration on Saturday authorized Johnson & Johnson’s single-dose adenovirus vector COVID-19 vaccine for adults aged 18 and older following Friday’s unanimous endorsement by the agency’s panel of outside experts.
In J&J’s 44,000-person global trial, the vaccine was found to be 66 percent effective at preventing moderate-to-severe COVID-19 four weeks after inoculation, and 100 percent effective in preventing hospitalization and death due to the virus.
There were very few serious side effects reported in the trial, which also offered preliminary evidence that the vaccine reduced asymptomatic infections. If that proves to be the case, it would mean COVID-19 vaccines may indeed reduce virus transmission as well as illness.